Fifteen years ago, the father of fashion designer, Lisa Gorman was diagnosed with two forms of blood cancer – lymphoma and leukaemia. As Lisa’s father began treatment, it became evident that more funding was required for research to uncover new treatments and better ways to manage the condition. It was during this period that Lisa … Continued
Dr Belinda Guo is the recipient of the 2019-2021 Gunn Family National Career Development Fellowship for Women in Haematology. For the past three years Belinda has researched novel blood biomarkers for predicting bone marrow failure in myeloproliferative neoplasms. During that time she has made great advances in identifying markers to monitor disease progression. Myeloproliferative neoplasm … Continued
Dinner of Hope 2021 Clinical trials are a pathway to hope for blood cancer patients. Trials provide access to next generation treatments when everything else has failed your body. However, clinical trials require human infrastructure that doesn’t exist in the ‘normal’ hospital setting. A clinical research fellow is required to identify trials that meet individual … Continued
Research into the treatment, known as chimeric antigen receptor T-cell therapy (CAR T-cell), shows it is more effective than current cancer treatments, but effectiveness does not imply value as far as health budgets are concerned. Australian and US blood cancer specialists reviewed the current measures of cost effectiveness and identified multiple strategies that could be … Continued
Forty per cent of patients with the most common form of aggressive non-Hodgkin lymphoma (diffuse large B-cell lymphoma) either relapse or are refractory to first line treatment with rituximab and chemotherapy. Stem-cell transplant was the only available treatment option thought to reliably induce cures until the approval of chimeric antigen receptor (CAR) T-cell therapy. However, … Continued
We are very proud to announce that the Snowdome Foundation has earned a place in the High-Growth Companies Asia-Pacific 2021 ranking. The ranking assesses millions of companies from 13 countries and Snowdome made it into the top 500 fastest-growing companies in the region. Only 71 companies from Australia made into the top 500 and we … Continued
Multiple myeloma has been a notoriously difficult blood cancer to manage. Relapses are common despite the advances that have been made in treatments over the years. Idecabtagene vicleucel (Ide-cel) a new chimeric antigen receptor (CAR) T-cell therapy, has just been approved by the FDA for relapsed refractory multiple myeloma. This is the first CAR T-cell … Continued
For anyone living with a blood cancer, chimeric antigen receptor T-cell therapy (CAR-T) is a lifeline. Leukaemia and lymphoma patients who have exhausted all other treatment options are given another chance at life. Their own immune system T-cells are genetically engineered to recognise cancer cells and destroy them. It is expected that the demand for … Continued
Myeloma is currently known as a terminal blood cancer. There is no cure, however there are many new treatments on the horizon which show great promise. Clinical trials are the gateway to accessing these new treatments, but not all myeloma patients are created equal when it comes to clinical trial eligibility. Geoff Nyssen wants to … Continued